- | Country : -
- | organs : -
- | Specialty : -
Extract
To demonstrate superiority in the overall survival (OS) of patients with progressive mCRPC treated with sunitinib plus prednisone (SP) versus placebo plus prednisone (PP) after failure of a docetaxel-based chemotherapy regimen.
Inclusion criteria
- Progressive metastatic castration-resistant prostate cancer after failure of a Docetaxel-based chemotherapy regimen